Nathan Enas

1.9k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Nathan Enas is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Nathan Enas has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Nathan Enas's work include Cancer Treatment and Pharmacology (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Statistical Methods in Clinical Trials (4 papers). Nathan Enas is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Statistical Methods in Clinical Trials (4 papers). Nathan Enas collaborates with scholars based in United States, United Kingdom and France. Nathan Enas's co-authors include Mace L. Rothenberg, Richard L. Schilsky, Anna Maria Storniolo, Maurizio Voi, Baoguang Han, Damian McEntegart, Nelson Kinnersley, Satrajit Roychoudhury, Kert Viele and Stacy Lindborg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Nathan Enas

25 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of historical control data for assessing treatment effects in clinical trials

2013 327 citations Kert Viele, Scott Berry et al. Pharmaceutical Statistics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Enas United States	16	492	358	274	183	176	25	1.4k
Mark D. Rothmann United States	16	443 0.9×	445 1.2×	382 1.4×	154 0.8×	324 1.8×	46	1.9k
Daniel Mulkerin United States	18	670 1.4×	366 1.0×	53 0.2×	155 0.8×	229 1.3×	79	1.2k
Chadi Nabhan United States	20	505 1.0×	609 1.7×	48 0.2×	211 1.2×	332 1.9×	97	1.5k
Fabienne Thomas France	26	829 1.7×	516 1.4×	34 0.1×	184 1.0×	332 1.9×	109	2.0k
Leonard Reyno United States	22	694 1.4×	332 0.9×	42 0.2×	110 0.6×	503 2.9×	46	1.6k
Chan Zeng United States	27	423 0.9×	748 2.1×	33 0.1×	93 0.5×	332 1.9×	63	2.4k
Frank Pétavy Netherlands	19	202 0.4×	234 0.7×	138 0.5×	66 0.4×	231 1.3×	33	1.1k
J. W. Kugler United States	15	616 1.3×	188 0.5×	54 0.2×	51 0.3×	152 0.9×	32	1.1k
Danika L. Lew United States	27	1.8k 3.6×	408 1.1×	131 0.5×	198 1.1×	697 4.0×	72	2.8k
James V. Tricoli United States	26	565 1.1×	1.1k 3.1×	48 0.2×	201 1.1×	433 2.5×	62	2.3k

Countries citing papers authored by Nathan Enas

Since Specialization

Citations

This map shows the geographic impact of Nathan Enas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Enas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Enas more than expected).

Fields of papers citing papers by Nathan Enas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Enas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Enas. The network helps show where Nathan Enas may publish in the future.

Co-authorship network of co-authors of Nathan Enas

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Enas. A scholar is included among the top collaborators of Nathan Enas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Enas. Nathan Enas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Claire, et al.. (2020). Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs. Pharmaceutical Statistics. 19(3). 276–290. 7 indexed citations

Tate, Sonya C., Valérie André, Nathan Enas, Benjamin Ribba, & Ivelina Gueorguieva. (2016). Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer. European Journal of Cancer. 66. 95–103. 15 indexed citations

Zecchin, Chiara, Ivelina Gueorguieva, Nathan Enas, & Lena E. Friberg. (2016). Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer. British Journal of Clinical Pharmacology. 82(3). 717–727. 22 indexed citations

Ganjoo, Kristen N., Sven de Vos, Brad Pohlman, et al.. (2014). Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma. 56(1). 42–48. 28 indexed citations

Jänne, Pasi A., Luis Paz‐Ares, Yun Oh, et al.. (2013). Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(1). 126–131. 28 indexed citations

Viele, Kert, Scott Berry, Beat Neuenschwander, et al.. (2013). Use of historical control data for assessing treatment effects in clinical trials. Pharmaceutical Statistics. 13(1). 41–54. 327 indexed citations breakdown →

Saif, Muhammad Wasif, Helmut Oettle, Walter L. Vervenne, et al.. (2009). Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas. The Cancer Journal. 15(4). 339–343. 44 indexed citations

Han, Baoguang, Nathan Enas, & Damian McEntegart. (2009). Randomization by minimization for unbalanced treatment allocation. Statistics in Medicine. 28(27). 3329–3346. 88 indexed citations

Robertson, Michael J., Brad S. Kahl, Julie M. Vose, et al.. (2007). Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. 25(13). 1741–1746. 196 indexed citations

10.

Carducci, Michael A., Luna Musib, Merrill S. Kies, et al.. (2006). Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 24(25). 4092–4099. 150 indexed citations

11.

Jänne, Pasi A., Luis Paz-Ares Rodríguez, Maya Gottfried, et al.. (2006). Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma. Journal of Clinical Oncology. 24(18_suppl). 7024–7024. 6 indexed citations

12.

Richards, Donald, Helmut Oettle, Walter L. Vervenne, et al.. (2005). Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas. Journal of Clinical Oncology. 23(16_suppl). 4092–4092. 6 indexed citations

13.

Robertson, Michael J., Brad S. Kahl, Julie M. Vose, et al.. (2005). A Phase II Study of Enzastaurin, a Protein Kinase C-β (PKCβ) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. Blood. 106(11). 934–934. 4 indexed citations

14.

Baselga, José, Antonio Llombart‐Cussac, Meritxell Bellet, et al.. (2003). Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of Oncology. 14(9). 1383–1390. 30 indexed citations

15.

Storniolo, Anna Maria, et al.. (1999). An investigational new drug treatment program for patients with gemcitabine. Cancer. 85(6). 1261–1268. 11 indexed citations

16.

Storniolo, Anna Maria, et al.. (1999). An investigational new drug treatment program for patients with gemcitabine. Cancer. 85(6). 1261–1268. 193 indexed citations

17.

Enas, Nathan, et al.. (1998). Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD)). Digestive Diseases and Sciences. 43(5). 993–1000. 90 indexed citations

18.

Enas, Nathan, et al.. (1992). Nizatidine versus placebo in active benign gastric ulcer disease: An eight-week, multicenter, randomized, double-blind comparison. Clinical Pharmacology & Therapeutics. 52(3). 307–313. 2 indexed citations

19.

Enas, Gregory G., et al.. (1990). Baseline Comparability in Clinical Trials: Prevention of “Poststudy Anxiety”. Drug Information Journal. 24(3). 541–548. 19 indexed citations

20.

Enas, Nathan. (1988). PASS: A Quick and Easy Power and Sample-Size Calculation Program. The American Statistician. 42(3). 229–229. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact